Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Clinical trial NCT03461276 · COMPLETED
Trial details
- NCT number
- NCT03461276
- Sponsor
- Araclon Biotech S.L.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-13
- Primary completion
- 2023-03-23
- Enrollment
- 134
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.